
|Videos|March 2, 2023
DREAMM-2: Belantamab Mafodotin for the Treatment of R/R MM
Sagar Lonial, MD, FACP, reviews the design and outcomes of the DREAMM-2 and ALGONQUIN studies investigating belantamab mafodotin in the treatment of relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5





























